Of note, JBJ-04-125-02 showed synergy with osimertinib, thus suggesting a potential benefit of combination therapies entailing an allosteric inhibitor and an ATP-competitive inhibitor for EGFR-mutated lung cancer [100,101]. Here, EGFR is linked to lung cancer.